Per Hildebrandt

5.9k total citations
23 papers, 710 citations indexed

About

Per Hildebrandt is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Per Hildebrandt has authored 23 papers receiving a total of 710 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 5 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Per Hildebrandt's work include Cardiovascular Function and Risk Factors (9 papers), Heart Failure Treatment and Management (8 papers) and Cardiac pacing and defibrillation studies (4 papers). Per Hildebrandt is often cited by papers focused on Cardiovascular Function and Risk Factors (9 papers), Heart Failure Treatment and Management (8 papers) and Cardiac pacing and defibrillation studies (4 papers). Per Hildebrandt collaborates with scholars based in Denmark, Finland and Sweden. Per Hildebrandt's co-authors include Finn Gustafsson, Lars Køber, Christian Torp‐Pedersen, Kristian Wachtell, Michael Hecht Olsen, Tine W. Hansen, Hans Ibsen, Thomas Sehestedt, Jørgen Jeppesen and Christian Torp-Petersen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Per Hildebrandt

22 papers receiving 672 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Per Hildebrandt Denmark	12	493	139	113	90	68	23	710
Enrico Vassallo Italy	11	523 1.1×	157 1.1×	129 1.1×	30 0.3×	79 1.2×	19	654
Emanuele Carbonieri Italy	14	587 1.2×	69 0.5×	84 0.7×	49 0.5×	51 0.8×	32	756
Donatella Ruggiero Italy	13	389 0.8×	134 1.0×	188 1.7×	43 0.5×	116 1.7×	19	645
Maria Panaretou Spain	8	612 1.2×	72 0.5×	184 1.6×	29 0.3×	65 1.0×	9	739
Eleanor Elstein Canada	9	380 0.8×	97 0.7×	295 2.6×	55 0.6×	35 0.5×	24	898
Pedro Morillas Spain	16	504 1.0×	80 0.6×	301 2.7×	37 0.4×	91 1.3×	66	768
Lilian Grigorian Shamagian Spain	15	440 0.9×	63 0.5×	134 1.2×	61 0.7×	25 0.4×	23	555
Filippo Scalise Italy	15	416 0.8×	70 0.5×	137 1.2×	30 0.3×	70 1.0×	44	608
Paolo Pauciullo Italy	14	281 0.6×	212 1.5×	302 2.7×	45 0.5×	31 0.5×	34	624
Filipe A. Moura Brazil	15	270 0.5×	234 1.7×	181 1.6×	117 1.3×	45 0.7×	45	689

Countries citing papers authored by Per Hildebrandt

Since Specialization

Citations

This map shows the geographic impact of Per Hildebrandt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Hildebrandt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Hildebrandt more than expected).

Fields of papers citing papers by Per Hildebrandt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Hildebrandt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Hildebrandt. The network helps show where Per Hildebrandt may publish in the future.

Co-authorship network of co-authors of Per Hildebrandt

This figure shows the co-authorship network connecting the top 25 collaborators of Per Hildebrandt. A scholar is included among the top collaborators of Per Hildebrandt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Hildebrandt. Per Hildebrandt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Køber, Lars, Christian Torp‐Pedersen, Jawad H. Butt, et al.. (2023). Specialized heart failure clinics versus primary care: Extended registry-based follow-up of the NorthStar trial. PLoS ONE. 18(6). e0286307–e0286307. 5 indexed citations

Ray, Kausik K., Aikaterini Bilitou, Carlos Aguíar, et al.. (2021). Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study. SHILAP Revista de lepidopterología. 43. 24–30. 27 indexed citations

Thune, Jens Jakob, Steen Pehrson, Jens Cosedis Nielsen, et al.. (2016). Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH). American Heart Journal. 179. 136–141. 26 indexed citations

Schou, Morten, Lars Videbæk, Lars Køber, et al.. (2013). Long term adherence in primary care versus a specialized heart failure clinic for outpatients with systolic heart failure. European Heart Journal. 34(suppl 1). 806–806. 1 indexed citations

Mathiasen, Anders Bruun, Per Winkel, Jens Peter Gøtze, et al.. (2010). High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Scandinavian Journal of Clinical and Laboratory Investigation. 71(1). 52–62. 29 indexed citations

Olsen, Michael Hecht, Thomas Sehestedt, Stig Lyngbæk, et al.. (2010). Urine Albumin/Creatinine Ratio, High Sensitivity C-Reactive Protein and N-Terminal Pro Brain Natriuretic Peptide - Three New Cardiovascular Risk Markers - Do They Improve Risk Prediction and Influence Treatment?. Current Vascular Pharmacology. 8(1). 134–139. 11 indexed citations

Rathcke, Camilla Noelle, Ilan Raymond, Caroline Kistorp, et al.. (2009). Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population. International Journal of Cardiology. 143(1). 35–42. 75 indexed citations

Sehestedt, Thomas, Jørgen Jeppesen, Tine W. Hansen, et al.. (2009). Risk prediction is improved by adding markers of subclinical organ damage to SCORE. European Heart Journal. 31(7). 883–891. 201 indexed citations

Hildebrandt, Per. (2009). Natriuretic Peptides~: Prediction of Cardiovascular Disease in the General Population and High Risk Populations. Disease Markers. 26(5-6). 227–233. 11 indexed citations

10.

Keiding, Hans, Per Hildebrandt, Thomas Burke, & George W. Carides. (2006). [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].. PubMed. 168(42). 3623–6. 1 indexed citations

11.

Hildebrandt, Per, Kristian Wachtell, Björn Dahlöf, et al.. (2005). Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study. Diabetic Medicine. 22(8). 1005–1011. 11 indexed citations

12.

Tarnow, Lise, Per Hildebrandt, Birgitte V. Hansen, K. Borch‐Johnsen, & H.‐H. Parving. (2004). Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia. 48(1). 149–155. 52 indexed citations

13.

Gustafsson, Finn, Christian Torp‐Pedersen, Lars Køber, Finn Gustafsson, & Per Hildebrandt. (1999). Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Journal of the American College of Cardiology. 34(1). 83–89. 96 indexed citations

14.

Torp‐Pedersen, Christian, Per Hildebrandt, Lars Køber, et al.. (1997). Does in-hospital ventricular fibrillation affect prognosis after myocardial infarction?. European Heart Journal. 18(6). 919–924. 31 indexed citations

15.

Seibæk, Marie, Carsten Sloth, Torben Hansen, et al.. (1997). Glucose tolerance status and severity of coronary artery disease in men referred to coronary arteriography. American Heart Journal. 133(6). 622–629. 36 indexed citations

16.

Gustafsson, Finn, Christian Torp‐Pedersen, Lars Køber, & Per Hildebrandt. (1997). Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. Journal of Hypertension. 15(7). 793–798. 31 indexed citations

17.

Gustafsson, Finn, et al.. (1997). Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. Research at the University of Copenhagen (University of Copenhagen). 3 indexed citations

18.

Melchior, Thomas, Niels Gadsbøll, Per Hildebrandt, Lars Køber, & C. Torp-Pedersen. (1996). Clinical Characteristics, Left and Right Ventricular Ejection Fraction, and Long-term Prognosis in Patients with Non-insulin-dependent Diabetes Surviving an Acute Myocardial Infarction. Diabetic Medicine. 13(5). 450–456. 16 indexed citations

19.

Melchior, Thomas, et al.. (1992). Recurrent acute idiopathic pericarditis treated with intravenous methylprednisolone given as pulse therapy. American Heart Journal. 123(4). 1086–1088. 7 indexed citations

20.

Hildebrandt, Per, et al.. (1981). Self-Monitoring of Blood Glucose Without a Meter. Diabetes Care. 4(3). 414–416. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact